A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this trial are to assess the safety, tolerability and efficacy of A197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with Dry Eye Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aramis Biosciences, Inc.
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Written informed consent must be obtained prior to any study-related assessments

• Have a history of Dry Eye Disease in both eyes for at least 12 months prior to Visit 1

• Willing and able to follow instructions and can be present for required study visits

Exclusion Criteria:

• Women who are pregnant or breastfeeding

• Use of topical ophthalmic medications, artificial tears, eye drops and gels in either eye

• Use of contact lenses within 90 days prior to Visit 1 and throughout the study

• Have had an ocular infection in either eye within 90 days prior to Visit 1